⁹⁰Y/¹⁷⁷Lu-DOTATOC: From Preclinical Studies to Application in Humans

The PRRT (Peptide Receptor Radionuclide Therapy) is a promising modality treatment for patients with inoperable or metastatic neuroendocrine tumors (NETs). Progression-free survival (PFS) and overall survival (OS) of these patients are favorably comparable with standard therapies. The protagonist in...

Полное описание

Библиографические подробности

Главные авторы:	Licia Uccelli, Alessandra Boschi, Corrado Cittanti, Petra Martini, Stefano Panareo, Eugenia Tonini, Alberto Nieri, Luca Urso, Matteo Caracciolo, Luca Lodi, Aldo Carnevale, Melchiore Giganti, Mirco Bartolomei
Формат:	Artigo
Язык:	Inglês
Опубликовано:	MDPI AG 2021-09-01
Серии:	Pharmaceutics
Предметы:	[<sup>177</sup>Lu]Lu-DOTATOC [<sup>90</sup>Y]Y-DOTATOC PRRT neuroendocrine tumors
Online-ссылка:	https://www.mdpi.com/1999-4923/13/9/1463
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!